Close

News Releases

News Release

Meridian Bioscience Announces It Will Supply Reagents for the Manufacturing of Tens of Millions of COVID-19 Antibody Tests Per Month

May 26, 2020 at 8:00 AM EDT

CINCINNATI, May 26, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that its SARS-CoV-2 antigens and related reagents are part of assays granted U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA), with projected production schedules of tens of millions of COVID-19 antibody tests per month.

Since the beginning of this public health emergency in January, Meridian has supported over 35 molecular diagnostic companies with critical master mixes and enzymes, enabling over 30 million COVID-19 molecular diagnostic tests. In April, Meridian began offering SARS-CoV-2 recombinant antigens to meet the growing need for antibody testing. Like Meridian’s molecular offerings, this immunological product line was quickly acknowledged for its ability to deliver high sensitivity and specificity assays. This level of quality, coupled with Meridian’s reliability of production and customer service, has led to high demand. Widespread COVID-19 testing, both molecular and antibody, is essential to front-line healthcare workers delivering care, researchers understanding the spread of infection, and scientists developing vaccines and therapies.

Jack Kenny, CEO of Meridian Bioscience commented, “We quickly responded to help test manufacturers around the world meet their COVID-19 testing requirements, through products with exceptional performance and scalable infrastructure. We remain committed to supporting the diagnostic industry during this global health crisis.”

For more information on partnering with Meridian Bioscience, please email Lourdes.Weltzien@meridianlifescience.com.

Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to projected production schedules, sales, product demand, revenue and the impact of COVID-19 on our business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the factors identified from time to time in Meridian’s filings with the Securities and Exchange Commission, particularly those included in the Part I, Item 1A “Risk Factors” section of our most recent Annual Report on Form 10-K which contains a list and description of uncertainties, risks and other matters that may affect Meridian. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on forward-looking statements.

About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.

Contact:
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone:  +1 513.271.3700
Email: mbi@meridianbioscience.com

MBI_Logo_Tagline_Blue.jpg

Source: Meridian Bioscience Inc.